Merck & Co, INC Form 4 insider transactions

Merck & Co., Inc. Chairman, CEO, and President Robert M. Davis sold 47,434 shares of common stock for approximately $5.6 million under a pre-arranged 10b5-1 trading plan.

Merck & Co.'s EVP and General Counsel, Jennifer Zachary, acquired 11,583 shares of common stock at $107.4 per share following the vesting of performance share units.

Merck & Co. EVP, Chief Info & Digital Officer David Michael Williams acquired 6,112 shares of common stock following the vesting of performance share units.

Merck & Co.'s SVP Fin. Global Controller, Dalton E. Smart III, acquired 1,066 shares of common stock at $107.4 per share following the satisfaction of performance share unit criteria.

Merck & Co. executive Joseph Romanelli acquired 5,703 shares of common stock at $107.40 per share, stemming from performance share unit vesting.

Merck's U.S. Market President, Johannes Oosthuizen, acquired 5,026 shares of common stock at $107.4 per share through the vesting of performance share units.

Merck & Co.'s EVP & CFO, Caroline Litchfield, acquired 15,852 shares of common stock at $107.4 per share through a performance-based award.

Merck's Executive VP & President, MRL, Dean Y. Li, acquired 20,469 shares of common stock at $107.4 per share, stemming from performance share unit vesting.

Merck's Chief Marketing Officer, Chirfi Guindo, acquired 9,865 shares of common stock on January 26, 2026, stemming from a performance share unit payout.

Merck & Co. EVP Richard R. DeLuca acquired 12,264 shares of common stock at $107.4 per share following the satisfaction of performance criteria for his performance share units.

Merck & Co., Inc. Chairman, CEO & President Robert M. Davis acquired 47,434 shares of common stock at $107.4 per share, following the satisfaction of performance criteria for performance share units.

Merck's Executive VP and President of MMD, Sanat Chattopadhyay, acquired 13,880 shares of common stock from a performance share unit payout.

A Merck & Co. director reported recent transactions involving the acquisition of phantom stock and disposition of common stock on December 31, 2025.

Merck & Co. Director Thomas H. Glocer reported an acquisition of 463.1389 phantom stock units, increasing his beneficial ownership of derivative securities.

Merck & Co. Director Mary Ellen Coe reported the acquisition of 285.0086 phantom stock units, to be settled in cash upon termination of service, and holds 29,231.5716 derivative securities.

Merck & Co. Chief Communications and Public Affairs Officer Cristal N. Downing reported the sale of 7,085 shares of common stock at $87 per share.

Merck & Co., Inc.'s EVP, Chief Information & Digital Officer, David Michael Williams, sold 8,614 shares of common stock for approximately $720,000.

Merck & Co. Director Christine E. Seidman reported the acquisition of 96.8069 phantom stock units and beneficial ownership of 18,775.7818 derivative securities.

Merck & Co. Director Thomas H. Glocer reported an acquisition of phantom stock units and updated his beneficial ownership of common stock and phantom stock.

Merck & Co. Director Mary Ellen Coe acquired 357.4407 phantom stock units, valued at $83.93 per unit, increasing her beneficial ownership to 28,684.663 units.

A Merck & Co. executive acquired shares through RSU vesting and subsequently sold a portion for tax purposes, correcting a prior vesting schedule.

Merck's Chief Marketing Officer, Chirfi Guindo, reported the acquisition of common stock from vested restricted stock units and the disposition of shares for tax purposes.

Merck & Co., Inc. Director Christine E. Seidman reported the acquisition of 102.6402 phantom stock units, which are cash-settled upon termination of service, under a Rule 10b5-1(c) plan.

Merck & Co. Director Thomas H. Glocer has reported the acquisition of 615.8413 phantom stock units and direct beneficial ownership of 5,100 shares of common stock, as detailed in a recent SEC Form 4 filing.

Merck & Co., Inc. Director Mary Ellen Coe reported the acquisition of 378.9793 phantom stock units and the disposition of 10 shares of common stock on June 30, 2025.

Merck & Co., Inc. Director Kathy J. Warden reported the disposition of 500 shares of common stock and the acquisition of 2,863.0921 phantom stock units valued at $76.84 per unit.

Merck & Co., Inc. Director Inge G. Thulin reported the acquisition of 2,863.0921 phantom stock units, increasing total beneficial ownership of derivative securities to 24,764.29 units.

Merck & Co., Inc. Director Christine E. Seidman has acquired 2,863.0921 phantom stock units as part of a deferred compensation plan, aligning her interests with the company's performance.

Merck & Co., Inc. Director Patricia F. Russo reported the acquisition of 2,863.0921 phantom stock units and updated her beneficial ownership of common stock and phantom stock.

Merck & Co., Inc. Director Paul Rothman reported the acquisition of 2,863.0921 phantom stock units on May 30, 2025, as part of a deferred compensation plan.